Biohaven Pharmaceuticals have announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Taldefgrobep alfa, a protein designed to inhibit the function of myostatin to increase muscle size and function.
Fast Track status is granted to drugs that show considerable potential for being able to treat life-threatening diseases, such as SMA. The designation means that the development and review processes of the promising drug can be streamlined in order to speed up being translated to the clinic.
Further Information
